Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Lopes MIF
 
RBR-8jyhxh
RCTcolchicineplaceboCOVID 19 hospitalizedhigh
19/19 inconclusive
    Salehzadeh
     
    IRCT20200418047126N1
    RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
    50/50 inconclusive
      Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.

      COVID-19 severe or critically meta-analysis

      COLCHIVID
       
      NCT04367168
      RCTcolchicineplaceboCOVID-19 severe or criticallyNA
      66/60 inconclusive
      • inconclusive 17 % decrease in death or transfer to ICU (PE)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).